Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 9/20 | 0.69 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007578 | 0.88 | ROCK1 (0.76) | ROCK1ROCK2KCNH2CCR2HRH3 | |
| SCHEMBL4147931 | 0.88 | ROCK1 (0.76) | ROCK1ROCK2KCNH2CCR2HRH3 | |
| SCHEMBL4007467 | 0.88 | ROCK1 (0.72) | ROCK1ROCK2KCNH2CCR2CCNT1 | |
| SCHEMBL4010349 | 0.86 | ROCK1 (0.69) | ROCK1ROCK2KCNH2CCR2PARP1 | |
| SCHEMBL4007602 | 0.84 | ROCK1 (0.82) | ROCK1ROCK2KCNH2CCR2KLKB1 | |
| SCHEMBL4361096 | 0.84 | ROCK1 (0.82) | ROCK1ROCK2KCNH2CCR2KLKB1 | |
| SCHEMBL4009197 | 0.83 | ROCK1 (0.66) | ROCK1ROCK2KCNH2CCR2KLKB1 | |
| SCHEMBL4010405 | 0.83 | ROCK1 (0.79) | ROCK1ROCK2KCNH2CCR2KLKB1 | |
| SCHEMBL4010730 | 0.82 | ROCK1 (0.82) | ROCK1ROCK2KCNH2CCR2KLKB1 | |
| SCHEMBL4006091 | 0.82 | ROCK1 (0.82) | ROCK1ROCK2KCNH2CCR2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885KCNH2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.